Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.

Mody R, Manjelievskaia J, Marchlewicz EH, Malik RE, Zimmerman NM, Irwin DE, Yu M

Clinical therapeutics6 Mar 2022Cited by 24 (Europe PMC)

PMID35264311DOI10.1016/j.clinthera.2022.01.017PepBankPUB-35264311

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to greater adherence than semaglutide at 6 months.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to greater adherence than semaglutide at 6 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAdherence at 6 months
Study
n = 52,568
Comparator
Semaglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Adherent patients
63.4%
dulaglutide at 6M
Adherent patients
47.8%
semaglutide at 6M
Source sentences
Summary
Compared to semaglutide initiators, dulaglutide initiators were more adherent (6M, 63.4% vs 47.8%; 12M, 54.4% vs 43.3%; both, P < 0.0001)
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases.
Summary · context
Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
Report a problemFND-3526431104
02HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to greater treatment persistence than semaglutide at 6 months.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to greater treatment persistence than semaglutide at 6 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePersistence at 6 months
Study
n = 52,568
Comparator
Semaglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Persistent patients
72%
dulaglutide at 6M
Persistent patients
62%
semaglutide at 6M
Source sentences
Summary
more persistent on therapy (6M, 72% vs 62%, 12M, 55.5% vs 45.3%, both, P < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases.
Summary · context
Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
Report a problemFND-3526431106
03HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to more persistence days than semaglutide at 6 months.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to more persistence days than semaglutide at 6 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseMean persistence days at 6 months
Study
n = 52,568
Comparator
Semaglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Measurements
Mean persistence
145 days
dulaglutide at 6M
Mean persistence
132 days
semaglutide at 6M
Source sentences
Summary
and had more mean days of persistence (6M, 145 vs 132, 12M, 254.3 vs 220.7; both, P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases.
Summary · context
Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
Report a problemFND-3526431108
04HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to greater adherence than semaglutide at 12 months.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to greater adherence than semaglutide at 12 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseAdherence at 12 months
Study
n = 27,674
Comparator
Semaglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Adherent patients
54.4%
dulaglutide at 12M
Adherent patients
43.3%
semaglutide at 12M
Source sentences
Summary
Compared to semaglutide initiators, dulaglutide initiators were more adherent (6M, 63.4% vs 47.8%; 12M, 54.4% vs 43.3%; both, P < 0.0001)
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases.
Summary · context
Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
Report a problemFND-3526431105
05HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to greater treatment persistence than semaglutide at 12 months.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to greater treatment persistence than semaglutide at 12 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePersistence at 12 months
Study
n = 27,674
Comparator
Semaglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Persistent patients
55.5%
dulaglutide at 12M
Persistent patients
45.3%
semaglutide at 12M
Source sentences
Summary
more persistent on therapy (6M, 72% vs 62%, 12M, 55.5% vs 45.3%, both, P < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases.
Summary · context
Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
Report a problemFND-3526431107
06HumanObservational studyOther
In adults with type 2 diabetes, dulaglutide initiation was linked to more persistence days than semaglutide at 12 months.
In plain wordsIn adults with diabetes, dulaglutide initiation was linked to more persistence days than semaglutide at 12 months.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseMean persistence days at 12 months
Study
n = 27,674
Comparator
Semaglutide
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Mean persistence
254.3 days
dulaglutide at 12M
Mean persistence
220.7 days
semaglutide at 12M
Source sentences
Summary
and had more mean days of persistence (6M, 145 vs 132, 12M, 254.3 vs 220.7; both, P < 0.001).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
This retrospective, observational cohort study used administrative claims data from three IBM MarketScan research databases.
Summary · context
Dulaglutide initiators were propensity score-matched, in a 1:1 ratio, to semaglutide initiators in each 6M and 12M follow-up cohort (26,284 and 13,837 pairs, respectively).
Report a problemFND-3526431109
07HumanObservational studyOther
In adults with type 2 diabetes new to GLP-1 receptor agonists, semaglutide initiators were less adherent than matched dulaglutide initiators at 6 and 12 months.
In plain wordsIn adults with type 2 diabetes, people starting semaglutide stuck to treatment less often than matched people starting dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseTreatment adherence at 6 and 12 months
Study
n: not reported in source
Comparator
Dulaglutide initiators
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · injectable · 6 and 12 months follow-upAs given in this study (human).
Measurements
Adherence
47.8%
semaglutide, 6M
Adherence
43.3%
semaglutide, 12M
Source sentences
Summary
Compared to semaglutide initiators, dulaglutide initiators were more adherent (6M, 63.4% vs 47.8%; 12M, 54.4% vs 43.3%; both, P < 0.0001
3 context sentences(design, population, supporting numbers)
Summary · context
At both 6M and 12M follow-up, dulaglutide initiators had significantly greater adherence and greater persistence compared with matched semaglutide initiators.
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
Data from adult patients with type 2 diabetes newly initiating treatment with dulaglutide or semaglutide between January 2018 and January 2020 (index date was defined as the earliest fill date), without evidence of glucagon-like peptide 1 receptor agonist use in the 6M baseline period, and with cont…
Report a problemFND-3526431101
08HumanObservational studyOther
In adults with type 2 diabetes new to GLP-1 receptor agonists, semaglutide initiators were less persistent on therapy than matched dulaglutide initiators at 6 and 12 months.
In plain wordsIn adults with type 2 diabetes, people starting semaglutide stayed on treatment less often than matched people starting dulaglutide.
Peptide
Semaglutide
Outcome
DecreasePersistence on therapy at 6 and 12 months
Study
n: not reported in source
Comparator
Dulaglutide initiators
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · injectable · 6 and 12 months follow-upAs given in this study (human).
Measurements
Persistence
62%
semaglutide, 6M
Persistence
45.3%
semaglutide, 12M
Source sentences
Summary
more persistent on therapy (6M, 72% vs 62%, 12M, 55.5% vs 45.3%, both, P < 0.001
3 context sentences(design, population, supporting numbers)
Summary · context
At both 6M and 12M follow-up, dulaglutide initiators had significantly greater adherence and greater persistence compared with matched semaglutide initiators.
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
Data from adult patients with type 2 diabetes newly initiating treatment with dulaglutide or semaglutide between January 2018 and January 2020 (index date was defined as the earliest fill date), without evidence of glucagon-like peptide 1 receptor agonist use in the 6M baseline period, and with cont…
Report a problemFND-3526431102
09HumanObservational studyOther
In adults with type 2 diabetes new to GLP-1 receptor agonists, semaglutide initiators had fewer mean days of persistence than matched dulaglutide initiators.
In plain wordsIn adults with type 2 diabetes, people starting semaglutide stayed on treatment for fewer days than matched people starting dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseMean days of persistence
Study
n: not reported in source
Comparator
Dulaglutide initiators
Outcome group
Treatment adherence and retention · Metabolic and weight
Studied dose
Dose not stated · injectable · 6 and 12 months follow-upAs given in this study (human).
Measurements
Mean days of persistence
132 days
semaglutide, 6M
Mean days of persistence
220.7 days
semaglutide, 12M
Source sentences
Summary
had more mean days of persistence (6M, 145 vs 132, 12M, 254.3 vs 220.7; both, P < 0.001
3 context sentences(design, population, supporting numbers)
Summary · context
At both 6M and 12M follow-up, dulaglutide initiators had significantly greater adherence and greater persistence compared with matched semaglutide initiators.
Summary · context
This study compared adherence, persistence, and treatment patterns among patients naïve to glucagon-like peptide 1 receptor agonists initiating once-weekly injectable treatment with dulaglutide versus semaglutide over 6-month (6M) and 12-month (12M) follow-up periods.
Summary · context
Data from adult patients with type 2 diabetes newly initiating treatment with dulaglutide or semaglutide between January 2018 and January 2020 (index date was defined as the earliest fill date), without evidence of glucagon-like peptide 1 receptor agonist use in the 6M baseline period, and with cont…
Report a problemFND-3526431103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice.

Summary

Results from this study9

Version history

Subjects

Publication types

MeSH terms

Keywords